Expanding global access to affordable medication for the prevention and treatment of PPH
Welcome to Oxytone Bioscience!
Oxytone Bioscience BV is a specialty pharmaceutical company focused on developing innovative oral medications for the prevention and treatment of postpartum hemorrhage (PPH). Our oral, heat-stable formulations have the potential to revolutionize maternal care by providing an affordable, accessible solution for PPH management. By tackling this urgent global health challenge, we aim to save hundreds of thousands of lives each year and significantly improve outcomes for mothers, especially in resource-limited settings.
Post-partum hemorraghe (PPH)
PPH affects 5% of all births globally, causing 300,000 maternal deaths annually, making it the leading cause of maternal mortality. Oxytocin, the WHO-recommended first-line treatment, is currently available only as a heat-sensitive injectable, requiring cold storage and skilled personnel for administration. These limitations, coupled with low product quality and accessibility in LMICs like Sub-Saharan Africa and South(-East) Asia, hinder effective care.
Oral, room-temperature stable formulation of oxytocin
Oxytone's tablet, designed for sublingual or buccal administration, eliminates the need for cold storage and skilled healthcare personnel, ensuring consistent product quality and enhanced accessibility, especially in low- and middle-income regions. In areas with high rates of non-facility births, these tablets can be pre-distributed to pregnant women or community health workers, providing an important tool for improving maternal health. Our innovative formulation and manufacturing process allow for affordable pricing, and the product is protected by granted patents across all major jurisdictions.
Following the successful completion of our Phase 1 clinical development program, a Phase 2 clinical development program is currently in the planning and organization stages.
Other products in the pipeline
In addition to our oxytocin formulation, Oxytone is developing alternative formulations of other existing postpartum hemorrhage (PPH) medications to further expand treatment options in low- and middle-income countries (LIMCs). These products, currently in development, aim to offer more accessible and flexible solutions for PPH, improving maternal health outcomes in resource-limited settings.
“Put bluntly, if you develop postpartum hemorrhage in the UK or France, it is extremely unlikely you will die. If you develop it in Pakistan or Nigeria, there is a significant chance that you will. This disparity applies to maternal deaths across the board: 99 per cent of maternal deaths take place in low- and middle-income countries.”
World Economic Forum
Picture by Pulitzer winner Lynsey Addario, from the award-wining series “Maternal Mortality”
Team
Oxytone is led by a seasoned team of pharmaceutical development professionals, including the inventors of 48 granted patents and key contributors to the development of 46 market-launched products.
Hans Platteeuw
Founder & CSO
Laurens Theunis
Executive Director
Donald Kalff
Investor & Corporate strategy
Collaborate to accelerate
We're committed to accelerating access to innovative solutions for patients by collaborating with like-minded stakeholders. Currently, we're always seeking co-development and/or investment partners to join us in the clinical development of our lead products for the prevention and treatment of PPH and related diseases. Reach out to us if you're interested in collaborating or investing!
Oxytone Bioscience BV
Hoofdstraat 43
5481 AA Schijndel, The Netherlands
General inquiries: info@oxytonebio.com
Partnering: partnering@oxytonebio.com
Company registration No.: KVK 60226730
​
​
